Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Davidsen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
FEBS Letters|October 29, 2002
Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug deliveryKent Jørgensen, Jesper Davidsen, Ole G Mouritsen
Biochimica Et Biophysica Acta|July 9, 2002
Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranesJesper Davidsen, Ole G Mouritsen, Kent Jørgensen
Biochimica Et Biophysica Acta|January 1, 2003
Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissueJesper Davidsen, Kent Jørgensen, Thomas L Andresen, et al.
Journal of Medicinal Chemistry|March 19, 2004
Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugsThomas L Andresen, Jesper Davidsen, Mikael Begtrup, et al.
Biochimica Et Biophysica Acta|December 3, 2005
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responsesJesper Davidsen, Ida Rosenkrands, Dennis Christensen, et al.
Molecular Cancer Therapeutics|November 16, 2004
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipidsSimon S Jensen, Thomas L Andresen, Jesper Davidsen, et al.
Lupus Science & Medicine|March 31, 2026
Pulmonary diseases in SLE: a population-based cross-sectional studyHenrik Zachar Langkilde, Jesper Davidsen, Stefan Harders, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
FEBS Letters|October 29, 2002
Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug deliveryKent Jørgensen, Jesper Davidsen, Ole G Mouritsen
Biochimica Et Biophysica Acta|July 9, 2002
Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranesJesper Davidsen, Ole G Mouritsen, Kent Jørgensen
Biochimica Et Biophysica Acta|January 1, 2003
Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissueJesper Davidsen, Kent Jørgensen, Thomas L Andresen, et al.
Journal of Medicinal Chemistry|March 19, 2004
Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugsThomas L Andresen, Jesper Davidsen, Mikael Begtrup, et al.
Biochimica Et Biophysica Acta|December 3, 2005
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responsesJesper Davidsen, Ida Rosenkrands, Dennis Christensen, et al.
Molecular Cancer Therapeutics|November 16, 2004
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipidsSimon S Jensen, Thomas L Andresen, Jesper Davidsen, et al.
Lupus Science & Medicine|March 31, 2026
Pulmonary diseases in SLE: a population-based cross-sectional studyHenrik Zachar Langkilde, Jesper Davidsen, Stefan Harders, et al.
Pageof 1